Using polygenic scores for identifying individuals at increased risk of substance use disorders in clinical and population samples by Barr, Peter B. et al.
Barr et al. Translational Psychiatry          (2020) 10:196 
https://doi.org/10.1038/s41398-020-00865-8 Translational Psychiatry
ART ICLE Open Ac ce s s
Using polygenic scores for identifying individuals at
increased risk of substance use disorders in clinical
and population samples
Peter B. Barr 1, Albert Ksinan2, Jinni Su3, Emma C. Johnson 4, Jacquelyn L. Meyers5, Leah Wetherill 6,
Antti Latvala 7,8, Fazil Aliev 1,9, Grace Chan 10, Samuel Kuperman11, John Nurnberger6,12,13, Chella Kamarajan 5,
Andrey Anokhin4, Arpana Agrawal 4, Richard J. Rose14, Howard J. Edenberg 6,15, Marc Schuckit16,
Jaakko Kaprio 7,17 and Danielle M. Dick1,18
Abstract
Genome-wide, polygenic risk scores (PRS) have emerged as a useful way to characterize genetic liability. There is
growing evidence that PRS may prove useful for early identification of those at increased risk for certain diseases. The
current potential of PRS for alcohol use disorders (AUD) remains an open question. Using data from both a population-
based sample [the FinnTwin12 (FT12) study] and a high-risk sample [the Collaborative Study on the Genetics of
Alcoholism (COGA)], we examined the association between PRSs derived from genome-wide association studies
(GWASs) of (1) alcohol dependence/alcohol problems, (2) alcohol consumption, and (3) risky behaviors with AUD and
other substance use disorder (SUD) criteria. These PRSs explain ~2.5–3.5% of the variance in AUD (across FT12 and
COGA) when all PRSs are included in the same model. Calculations of area under the curve (AUC) show PRS provide
only a slight improvement over a model with age, sex, and ancestral principal components as covariates. While
individuals in the top 20, 10, and 5% of the PRS distribution had greater odds of having an AUD compared to the
lower end of the continuum in both COGA and FT12, the point estimates at each threshold were statistically
indistinguishable. Those in the top 5% reported greater levels of licit (alcohol and nicotine) and illicit (cannabis and
opioid) SUD criteria. PRSs are associated with risk for SUD in independent samples. However, usefulness for identifying
those at increased risk in their current form is modest, at best. Improvement in predictive ability will likely be
dependent on increasing the size of well-phenotyped discovery samples.
Introduction
Alcohol misuse is one of the leading contributors to
preventable mortality and morbidity worldwide1–3. Iden-
tifying individuals at heightened risk for developing
alcohol-related problems remains an important goal of
medical practitioners. One important risk factor for
alcohol misuse is one’s own genetic liability. Twin and
family studies indicate that genetic influences on alcohol
use disorders (AUD) account for ~50% of the variation in
the population4. Genome-wide association studies
(GWASs) have identified multiple variants associated with
AUD5–7, alcohol consumption7,8, and maximum alcohol
intake9. Using information from these GWASs, we are
now able to aggregate risk across the genome by creating
polygenic risk scores (PRS) in independent samples5,6,8,10.
Beyond being useful for research purposes, researchers
have begun to examine the potential of PRS to predict risk
for medical outcomes in clinical settings. PRS for cor-
onary artery disease (CAD), atrial fibrillation (AF), type 2
diabetes (T2D), inflammatory bowel disease (IBS), and
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breast cancer (BC) have been found to be as predictive of
these diseases as well known monogenic mutations11,
which tend to be rarer, and could lead to improved
screening for larger numbers of individual who are at risk.
Individuals in the top 5% of the PRS distributions had ~3
fold likelihood of having CAD, AF, T2D, IBS, or BC
compared to the bottom 95%. For obesity, individuals in
the top PRS decile were on average 13 kg heavier than
those in the bottom decile12. These studies demonstrate
the potential for identifying individuals at heightened risk
for various medical conditions using PRS. Given that
AUD is a moderately heritable trait and GWAS for
alcohol-related phenotypes are beginning to identify
numerous variants associated with these outcomes, PRS
for alcohol-related outcomes may be also able to identify
individuals at heightened risk of developing an AUD.
In the current analysis, we tested PRS in two target
samples, a population-based sample and a clinically
ascertained sample of families deeply affected by AUD,
to evaluate the current state of alcohol-related PRS in
relation to AUD and identifying those at heightened
risk. We use several discovery samples from large-scale
GWAS to create three PRS: a meta-analysis of two
GWASs on alcohol-related problems5,6, a recent large-
scale GWAS of alcohol consumption8, and a GWAS for
risky behaviors, including alcohol use13. We chose to
test PRS based on multiple alcohol-related GWAS
because multiple lines of evidence indicate alcohol
consumption and dependence have only partially shared
genetic etiology5,6,14,15. Additionally, we include a PRS
for general risk behavior as there is robust evidence that
the genetic risk for alcohol and other substance use
disorders is shared with other disorders and behaviors
related to reduced inhibitory control16–18. Similar to
recent work for specific medical conditions11, we com-
pare the upper end of the PRS distribution at various
thresholds (top 20, 10, and 5%) to examine whether
focusing on these upper parts of the distribution provide
additional information in identifying those at increased
risk of developing an AUD. We acknowledge the
exploratory nature of these analyses and the arbitrary
nature of our thresholds in the absence of well-defined
clinical risk scores, such as those for medical conditions
like hypertension. Finally, we test the association of
these PRSs with other substance use disorders (includ-
ing nicotine and illicit substance use disorders), based
on the robust finding that substance use disorders share
an underlying genetic architecture, with the majority of
the heritability shared across substances16–18.
Methods
Samples
The FinnTwin12 Study (FT12) is a population-based
study of Finnish twins born 1983–1987 identified
through Finland’s Central Population Registry. A total of
2705 families (87% of all identified) returned the initial
family questionnaire late in the year in which twins
reached age 11. Twins were invited to participate in
follow-up surveys when they were ages 14, 17, and
approximately 22 (during young adulthood). An inten-
sively studies sample was selected as 1035 families,
among whom 1854 twins were interviewed at age 14.
The interviewed twins were invited as young adults to
complete the Semi-Structured Assessment for the
Genetics of Alcoholism (SSAGA)19,20 interview (n=
1,347) and provide DNA samples (see Kaprio 2013 for a
full description). The current analysis uses data from the
young adult wave (mean age= 21.9; range 20–26),
which included retrospective lifetime diagnoses.
The Collaborative Study on the Genetics of Alcohol-
ism (COGA) is a sample of high-risk families ascer-
tained through adult probands in treatment for AUD
and a smaller set of comparison families from the same
communities. In the first 10 years, probands along with
all willing first-degree relatives were assessed; recruit-
ment was extended to include additional relatives. Data
collection included the SSAGA19, neurophysiological
and neuropsychological protocols, and collection of
blood for DNA. In 2004, COGA began a prospective
study of adolescents and young adults, targeting
assessment of youth aged 12–22 from COGA families
where at least one parent had been interviewed. These
young participants were re-assessed every two years.
The sample is racially/ethnically diverse (60.6% non-
Hispanic White, 24.9% Black, 11.1% Hispanic, and 3.4%
other). Most (84%) have GWAS data. A full description
of the COGA sample is available elsewhere21–23. For the
present study, we only focused on COGA participants of
empirically assigned (as verified from GWAS data)
European ancestry (n= 7599) because each of the dis-
covery GWAS samples were primarily of European
ancestry. Ancestral mismatch between discovery and
target samples can lead to bias in the performance of
polygenic scores24.
Measures
Alcohol use disorder (AUD)
We used SSAGA interviews to construct lifetime cri-
teria counts of DSM-5 AUD25 in each sample. Because
individuals in COGA are potentially interviewed multiple
times, we used the highest criteria count ever reported by
each subject. In FT12, lifetime criteria counts were mea-
sured at the young adult interview. In addition to criteria
counts, we created AUD thresholds for those who met
criteria for mild (2+ criteria), moderate (4+ criteria), or
severe (6+ criteria) AUD25 without clustering. In both
FT12 and COGA, individuals who had never initiated
alcohol use were coded as missing.
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Other substance use disorders (SUD)
We constructed lifetime criteria counts of cannabis,
cocaine, and opioid use disorders based on DSM-5 cri-
teria. We measured nicotine dependence criteria using the
Fagerstrom Test for Nicotine Dependence (FTND), which
assesses six criteria and has values ranging from 0 to 10 in
both COGA and FT12. Because many illicit SUDs were
not measured or rare in the FT12 data, we limit analyses
of illicit SUD to COGA. Like AUD, these criteria counts
represent the maximum reported for each respondent
across the course of the study. Criteria counts for each
substance were limited to those who indicated ever using
the corresponding substance. In the case of FTND, this is
limited to those who report smoking 100+ cigarettes in
their lifetime.
Polygenic scores (PRS)
We created PRS derived from publicly available large-
scale GWASs. Information on genotyping and quality
control is available in the Supplementary information
(Section 1). We created PRS using a Bayesian regression
and continuous shrinkage method (PRS-CS)26. PRS-CS
uses LD information from an external reference panel
(1000 Genomes Phase III European subsample) to esti-
mate the posterior effect sizes for each SNP in a given set
of GWAS summary statistics. Both empirical tests and
simulations have shown improved predictive power above
traditional methods of score construction26. For compu-
tational purposes, we limited the SNPS for score creation
to HapMap3 SNPs that overlapped between the original
GWAS summary statistics, the LD reference panel, and
the target samples for score creation. We converted PRS
to Z-scores for interpretation.
We used four primary discovery GWASs to create three
different PRSs. The first was from a recent GWAS of
number of alcoholic drinks per week in approximately
one million individuals provided by the GWAS &
Sequencing Consortium of Alcohol and Nicotine Use
(GSCAN)8. We obtained GSCAN summary statistics with
all Finnish (which included FinnTwin12) and 23andMe
(which are not publicly available) cohorts removed
(available N= 534,683). The PRS for alcohol problems
were derived from a meta-analysis of two GWASs: a
GWAS on the problem subscale from the Alcohol Use
Disorders Identification Test (questions 4–10; AUDIT-P)
in 121,604 individuals from the UK Biobank6 and the
Psychiatric Genomcs Consurtium’s (PGC) GWAS of
alcohol dependence (N= 46,568)5. Both FT12 and COGA
were in the initial AD GWAS and we obtained summary
statistics with each cohort removed (meta-analysis results
available in supplemental info Tables S1, S2 and Figs. S1,
S2). Finally, we derived a PRS for risky behaviors from a
GWAS of the first prinicipal component of four risky
behaviors (drinks per week, ever smoking, propensity for
driving over the speed limit, and number of sexual part-
ners) from 315,894 individuals in the UK Biobank
(UKB)13. While this PRS does include alcohol consump-
tion and smoking, it captures the shared variance between
these substance use measures and the other two risky
behaviors. These polygenic scores covered the domains of
alcohol consumption (GSCAN DPW), alcohol problems
(PROB ALC), and general externalizing (RISK PC).
Analytic strategy
We first identified the predictive power for each PRS
in both COGA and FT12 using the change in R2 above a
baseline model with sex, age of last observation, the first
ten ancestral principal components (PCs), genotyping
array, and data collection site (these latter two were only
included in COGA analyses). We used linear/general-
ized-linear mixed-effects models with random inter-
cepts to adjust for clustering at the family level and a
pseudo-R2 for mixed models27. In addition to the pre-
dictive power of individual PRS, we estimated the con-
ditional effect of all PRS on AUD criteria to examine
whether each PRS explained unique variance in AUD
criteria. We also calculated the area under the curve
(AUC) of the conditional model containing all con-
tinuous PRS to estimate sensitivity/specificity28. AUC
provides an estimate of the probability a randomly
selected case has predicted value more extreme than
that of a randomly chosen control29. An AUC of 0.5
indicates that a classifier does not provide any useful
information in determining cases from controls (see
supplemental information Section 3). We next divided
PRSs at several thresholds (80th, 90th, and 95th per-
centiles) to examine whether there was a non-linear
increase in risk of AUD (using symptom severity
thresholds of AUD) across the PRS continuum. Finally,
we compared mean values of other substance use out-
comes for the top 5% in each PRS to those in the bottom
95%. We selected this threshold based in the increased
prevalence of AUD in those in the top 5% of the PRS
distributions (see Fig. S3). All code is available upon
request from the corresponding author.
Results
Table 1 presents the descriptive statistics for each of the
samples. Each sample has slightly more female than male
participants. The mean number of AUD criteria (3.44) in
COGA was relatively high, as COGA was primarily
ascertained for families with multiple AUD members.
COGA participants report a mean of 4.17 for FTND cri-
teria. For other SUD criteria in COGA, there are a sub-
stantial number of participants who report non-zero
levels of criteria, though criteria counts for cannabis,
cocaine, and opioid use disorders are zero-inflated (see
Table 1). The mean number of AUD and FTND criteria in
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the population-based FT12 sample were 1.63 and 2.57,
respectively.
Predictive power of PRS
Across each sample and PRS, we observed significant
associations between PRS and AUD criteria, even after
correcting for a false discovery rate (FDR)30 of 5%. In
COGA the GSCAN DPW PRS was most strongly asso-
ciated with AUD criteria (ΔR2= 0.017), followed closely
by the RISK PC PRS (ΔR2= 0.016), and lastly the PROB
ALC PRS (ΔR2= 0.012). We see a similar pattern in FT12,
where the GSCAN DPW PRS was the strongest associa-
tion (ΔR2= 0.030), the RISK PC PRS was slightly weaker
(ΔR2= 0.023), and the PROB ALC PRS performed the
worst (ΔR2= 0.001).
Next, we determined whether each of these PRS con-
tributed to AUD criteria in a model containing all three,
simultaneously. Figure 1 presents the parameter estimates
for the independent and conditional effect of each PRS in
both COGA and FT12. In the conditional model for
COGA, each of the PRSs remains significantly associated
with AUD criteria, though the associations are attenuated
(conditional model ΔR2= 0.025). In FT12, the PRS for
RISK PC and GSCAN DPW remain significant in the
conditional model, while the association for PROB ALC
PRS is no longer significant (conditional model ΔR2=
0.035). We averaged the three PRS into one composite
PRS score in COGA and averaged the RISK PC and
GSCAN DPW PRS in FT12 to carry forward in the fol-
lowing analyses.
Finally, we assessed the sensitivity/specificity of these
combined PRS by calculating the AUC from receiver
operating characteristic (ROC) curves, presented in Fig. 2.
AUC from the full model (including both continuous PRS
and covariates) for each level of AUD severity ranged
from 0.67 to 0.74 in COGA and from 0.65 to 0.76 in FT12.
Comparing the AUC for the models with and without
PRSs, including the PRS only provided a slight increase in
AUC.
Increase in risk across the polygenic continuum
In order to estimate whether individuals at the extreme
end of the PRS distribution were at elevated risk of AUD,
we compared the risk of AUD between those above and
below a given threshold in the distribution. We divided
these PRSs at the 80th, 90th, and 95th percentile in each
sample and estimated the odds ratio (OR) for AUD in the
top portion of the distribution relative to the bottom
portion of the distribution (e.g., splitting at the 80th
percentile compares the top 20% to the bottom 80%).
Table 2 provides the estimates for all of those models.
Across each threshold for AUD severity in COGA, we
observed a similar pattern where, as expected, those in the
upper end of the polygenic distribution had greater odds
of meeting criteria for AUD. However, regardless of the
threshold, the OR’s at each threshold were roughly
equivalent. For example, in the case of severe AUD, when
dividing 80th percentile (OR= 1.98; 95% CI= 1.53, 2.57),
90th percentile (OR= 2.02; 95% CI= 1.73, 2.36), or 95th
percentile (OR= 1.96; 95% CI= 1.59, 2.40), all of con-
fidence intervals for the point estimates overlap. In FT12,
there was a similar pattern. Though some of the point
estimates appear to increase as the thresholds become
more restrictive, the confidence intervals again overlap.
Table 1 Descriptive Statistics for FT12 and COGA samples.
Sample N Mean/% Median % 0 SD Min Max
COGA Female 7599 52.84% – – – – –
Age 7599 36.94 – – 14.77 12 91
DSM-5 AUD criteria 7300 3.44 2 28.79% 3.63 0 11
DSM-5 CUD criteria 5051 2.37 1 48.19% 3.13 0 11
DSM-5 CoUD criteria 2404 3.18 0 50.17% 4.13 0 11
DSM-5 OUD criteria 1663 2.05 0 62.96% 3.51 0 11
FTND count 3701 4.12 4 14.02% 2.74 0 10
FT12 Female 1251 54.40% – – – – –
Age 1247 21.94 – – 0.77 21 26
DSM-5 AUD criteria 1215 1.63 1 34.57% 1.84 0 11
FTND count 631 2.57 2 21.55% 2.13 0 10
The N reflects those who report lifetime ever use of that substance. All criteria counts limited to individuals who had initiated use of that substance. The % 0
represents the percentage of participants who have initiated use and have no reported criteria.
AUD alcohol use disorder, CUD cannabis use disorder, CoUD cocaine use disorder, OUD opioid use disorder, FTND Fagerstrom test for nicotine dependence (limited to
those who report ever smoking 100 cigarettes).
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Fig. 1 Parameter estimates for PRS in independent and conditional models. Parameter estimates (with 95% confidence intervals), from linear
mixed models for alcohol use disorder (AUD) criteria regressed on polygenic risk scores (PRS) for drinks per week (GSCAN DPW), problem alcohol use
(PROB ALC), and risky behaviors (RISK PC) in COGA and FT12. Independent=model with only corresponding PRS. Conditional=model with all PRS
included. Adjusted for age, sex, first 10 ancestral principal components, genotyping array, and data collection site (only COGA for the latter two). All
tests were two-sided.
Fig. 2 ROC curves for baseline and PRS models. Receiver operating characteristic (ROC) curves for baseline models (covariates only) and polygenic
risk score (PRS) models (PRS+ covariate) for each level of severity in alcohol use disorder (AUD). Area under the curve (AUC) for the PRS model (Full
AUC) and change in in AUC from Base to PRS model (Δ AUC) is presented each cell. AUC provides an estimate of the probability a randomly selected
subject with the condition has a test result indicating greater suspicion than that of a randomly chosen subject without the condition29. An AUC of
0.5 indicates that a classifier does not provide any useful information in determining cases from controls.
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Examining the substance use phenome of the extreme end
of the polygenic risk continuum
We compared the likelihood of substance-related out-
comes in individuals in the top 5% of each of the PRS in
COGA and FT12 (adjusted for covariates). Figure 3 presents
the mean lifetime criteria endorsed for a variety of sub-
stance use disorders (alcohol, cannabis, cocaine, nicotine,
and opioid) for individuals in the top 5% for each PRS
relative to the bottom 95% of each PRS. In COGA, indivi-
duals in the top 5% of the PROB ALC, RISK PC, and/or
GSCAN DPW PRS had significantly higher levels of alcohol
(0.25–0.31 SD), while individuals in the top 5% of the PROB
ALC and RISK PC had higher mean nicotine criteria
(0.10–0.16 SD) than those in the bottom 95% of the PRS
distribution. Those in the top 5% of the RISK PC PRS also
endorsed a higher number of criteria for cannabis use dis-
order (0.14 SD) and opioid use disorder (0.19 SD). In FT12,
those in the top 5% in the top 5% of the RISK PC and
GSCAN DPW PRS had significantly higher levels of AUD
criteria (0.25–0.31 SD) but did not differ on FTND criteria.
Overall, individuals in the top 5% of any PRS report
greater levels of any substance, though being in the top 5%
of the RISK PC PRS is associated with the most other
substances. These PRS are modestly correlated with one
another in both COGA (rRISK PC* PROB ALC= 0.34; rGSCAN
DPW*RISK PC= 0.49; rGSCAN DPW* PROB ALC= 0.40) and
FT12 (rRISK PC*PROB ALC= 0.25; rGSCAN DPW*RISK PC= 0.50;
rGSCAN DPW* PROB ALC= 0.35), but each captures unique
information related to the genetics of substance use
problems (and other risky behaviors).
Discussion
Researchers have begun to evaluate the potential for use
of PRS (for a variety of medical phenotypes)11,12 in clinical
settings. In this analysis, we examined the current predictive
power and strength of association between several PRSs and
a variety of SUDs, with a focus on AUD in both a clinically
ascertained and a population-based sample. We were
interested in (1) which scores based on available GWASs
provided the strongest association with alcohol use dis-
order, whether these scores explained unique variance in
AUD in a conditional model, and how well these scores
discriminated between cases and controls; (2) what the risk
of AUD was for those at the upper end of the risk con-
tinuum compared to the bottom; and 3) the levels of
substance use disorder criteria for individuals at the top
5% of the polygenic score continuum compared to
remaining 95%.
Table 2 Odds ratios for those at extreme end of the PRS continuum.
Sample Phenotype Prevalence Split N Cases OR 95 % CI Low 95 % CI High
Mild AUD 57.06% 80% 998 1.96* 1.70 2.26
COGA Mild AUD 57.06% 90% 501 1.81* 1.49 2.19
Mild AUD 57.06% 95% 258 1.89* 1.45 2.47
Moderate AUD 37.44% 80% 738 2.07* 1.79 2.38
COGA Moderate AUD 37.44% 90% 383 1.94* 1.60 2.34
Moderate AUD 37.44% 95% 201 1.98* 1.53 2.57
Severe AUD 25.89% 80% 534 2.02* 1.73 2.36
COGA Severe AUD 25.89% 90% 285 1.96* 1.59 2.40
Severe AUD 25.89% 95% 146 1.81* 1.38 2.39
Mild AUD 41.98% 80% 123 1.78* 1.21 2.61
FT12 Mild AUD 41.98% 90% 68 2.35* 1.41 3.93
Mild AUD 41.98% 95% 32 1.94 0.97 3.88
Moderate AUD 13.91% 80% 55 2.85* 1.72 4.74
FT12 Moderate AUD 13.91% 90% 32 3.50* 1.85 6.64
Moderate AUD 13.91% 95% 15 3.14* 1.33 7.42
Severe AUD 3.79% 80% 16 2.84* 1.37 5.87
FT12 Severe AUD 3.79% 90% 12 4.41* 2.04 9.54
Severe AUD 3.79% 95% 5 2.98 0.96 9.30
All models control for sex, age at last interview, and first 10 principal components. Models for COGA also included data collection site and genotyping array. N Cases
= number of individuals who meet criteria for a given level of AUD and are in the top portion of the split.
*p < 0.05 (two-sided) after correcting for 5% false discovery rate (FDR).
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In terms of which polygenic scores were the most pre-
dictive, we considered three scores: one based on pro-
blematic alcohol use (PROB ALC), one based on alcohol
consumption (GSCAN DPW), and one based on general
risky behaviors (RISK PC), as twin and family studies have
shown alcohol and other risk behaviors to be genetically
correlated traits6,14–18. In both samples, the GSCAN DPW
PRS was the most strongly associated, followed closely by
the RISK PC PRS. When we included all of the PRS in one
model, all three PRS were associated with AUD criteria in
COGA. Only the RISK PC and GSCAN DPW PRS were
associated with AUD criteria in FT12. Overall, the unique
contributions of each PRS reinforce the notion that the
genetics of AUD are multifaceted, comprised of risk for
level of consumption, alcohol-related problems, and
behavioral disinhibition31,32. Evaluating the AUC for the
combined PRS revealed the combined effect of PRSs only
marginally improved the AUC, similar to recent analyses
for coronary artery disease33 and ischemic stroke34. We
ran a series of sensitivity analyses to test whether differ-
ences across the samples reflected age differences rather
than differences in ascertainment. Restricting COGA to
participants under 30 did not fundamentally change the
results (see Supplementary information Section 4, Table
S3, and Fig. S4). Evaluating the AUC for the combined
PRS revealed the combined effect of PRSs only marginally
improved the AUC over models with just covariates.
In an exploratory approach, we chose a series of more
restrictive thresholds to divide the PRS distribution. The
odds of having an AUD were statistically indistinguishable
across each of the thresholds in both COGA and FT12. Even
though the point estimates increased in some cases, the
confidence intervals around these estimates were relatively
large and they did not differ significantly. Additionally, there
were only a small number of individuals in the severe cate-
gory in FT12 and we urge caution in interpreting these
estimates. Finally, the top 5% of the continuum for each PRS
reported elevated rates of other SUD criteria (cannabis,
cocaine, opioid, and nicotine use disorders) compared to the
bottom 95%. The RISK PC PRS was most associated with
higher mean levels of SUD criteria, suggesting that risk for
externalizing may be particularly useful in identifying indi-
viduals at risk for multiple SUDs.
These initial findings suggest the current PRSs are unlikely
to prove useful for SUDs in a clinical setting. Being able to
eventually identify those at heightened risk for SUDs may
allow for more targeted early intervention and prevention.
However, before this is possible, larger discovery GWAS
across substance use phenotypes with PRS that explain
greater portions of the variance will be necessary. As GWAS
sample sizes for SUDs increase, we will likely see increases in
effect sizes35. Additionally, using multivariate techniques to
model the shared genetic architecture across existing SUD
GWAS to include both aspects of externalizing and inter-
nalizing (e.g. depression, anxiety) may also improve predic-
tion36,37. Inclusion of genetic data in a clinical setting will also
require that psychiatrists and clinicians receive greater
training in genetics and/or that they partner with genetic
Fig. 3 Top 5% of PRS Continuum. Mean levels of substance use disorder (SUD) criteria for alcohol, cannabis, cocaine, nicotine, and opioid use
disorders for top 5% of each polygenic risk score (PRS) compared to the bottom 95%. Black bar represents mean of bottom 95% of each sample. 95%
confidence intervals estimated using 1000 bootstrap resampling.
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counselors, so they are both better able to understand what
increased genetic risk means and be able convey that infor-
mation accurately to their patients38,39. In addition to clinical
utility, we must ensure that regulations and protections
surrounding the use of genetic information in clinical settings
can adequately protect the rights of individuals who are
identified to be “at risk.”
This research has several important limitations. First, all
analyses were limited to individuals of European ancestry
because the discovery GWASs available were conducted in
individuals of primarily European ancestry. It will be
important to ascertain sizable samples of subjects with non-
European ancestries to properly estimate the predictive
utility of PRS in non-European samples. This is especially
important for racial-ethnic minorities so that health dis-
parities are not further perpetuated40. Second, our use of
lifetime diagnoses may obscure the impact of changing
genetic influences on the development of AUD across the
life course41,42. Future work should draw on longitudinal
data to examine the ways in which the strength of asso-
ciations for PRS changes with the age of the target sample.
Third, UKB was a large portion of the discovery sample for
each of the GWAS used to create PRS. To the degree that
UKB is biased, each of the PRS in these analyses will also
reflect that bias43. Finally, these analyses examined the
marginal influence of PRS, independent of environment.
Processes of gene-environment interaction (GxE) are well
documented in alcohol misuse44–47. Incorporating envir-
onmental information along with PRS in a methodologically
rigorous manner will be an important next step in devel-
oping clinically predictive algorithms.
Polygenic scores are becoming better powered and starting
to explain non-trivial portions of variance. We examined the
current state of PRS for substance use, with a focus on AUD.
Each of the PRSs analyzed here were associated with AUD.
However, the maximum variance explained by any single
score was still small (~2%). Individuals at the top of the PRS
continuum had elevated rates of multiple substance use
problems, but these differences across the PRS continuum
are unlikely to be of broad clinical use in their current state.
As GWAS discovery samples become larger and we are
better able to model the complex relationship between
genotype and phenotype, polygenic scores may eventually be
useful in a clinical setting.
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